Dualyx completes series A financing to advance Treg therapies for autoimmune diseases
May 15, 2023
Dualyx NV has completed a €40 million (US$44 million) series A financing, allowing the company to advance its lead autoimmune program, DT-001, as well as its pipeline of regulatory T-cell (Treg) candidates.